Clearside Biomedical Inc
XMUN:CLM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Clearside Biomedical Inc
XMUN:CLM
|
US |
|
AIC Mines Ltd
ASX:A1M
|
AU |
|
N
|
Nov Inc
XMUN:NO8
|
US |
|
Swatch Group AG
SIX:UHRN
|
CH |
|
B
|
Beyond Meat Inc
SWB:0Q3
|
US |
|
A
|
Andlauer Healthcare Group Inc
F:3LT
|
CA |
|
Toast Inc
NYSE:TOST
|
US |
|
S
|
Starpharma Holdings Ltd
F:PQ6A
|
AU |
|
N
|
National Bank of Greece SA
F:NAGF
|
GR |
|
Grupa Kety SA
F:GQ2
|
PL |
|
M
|
mBank SA
SWB:BRU
|
PL |
|
T
|
TravelSky Technology Ltd
F:TVL
|
CN |
|
A
|
Allgeier SE
XBER:AEIN
|
DE |
|
East Money Information Co Ltd
SZSE:300059
|
CN |
|
L
|
L3harris Technologies Inc
SWB:HRS
|
US |
|
Q
|
Qualcomm Inc
XHAM:QCI
|
US |
|
Family Zone Cyber Safety Ltd
OTC:FMZNF
|
AU |
|
A
|
Atlantia SpA
F:AU9
|
IT |
|
AO World PLC
LSE:AO
|
UK |
Clearside Biomedical Inc
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
